JACC-Basic to Translational Science-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2023-08-07 Jovanny 来自上海

请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀

58 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2022-05-04 14768f19m17暂无昵称

请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？

274 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2024-02-15 ms4000001004434861 来自艾奥瓦

审稿速度:3.0 | 投稿命中率:50.0
经验分享：正在送审

26 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2023-06-13 来来搞起来自安徽省

提交之后一直没收到邮件正常吗

67 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2022-06-16 14768f19m17暂无昵称

我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃

343 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2023-03-28 ms7000001526503726

问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2021-12-29 msSSSSSD

ORCIDID是什么？怎么注册？

252 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2021-12-27 桑晒麦拉

投稿时候是否一定要提供每个作者的ORCIDID?

191 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2151591, encodeId=864821515916e, content=请教各位大佬，投稿之后很快“Manuscript Under Review”，是不是只是editorial review；一般这个到外审或者作出决定需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Mon Aug 07 10:54:13 CST 2023, time=2023-08-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1216812, encodeId=deb112168121f, content=请问有同行知道这个杂志的审稿周期吗，已经under review 37天了，不胜感激，想发个催稿邮件合适吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=274, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Wed May 04 16:23:33 CST 2022, time=2022-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187349, encodeId=26ef218e3490e, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：正在送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79709173987, createdName=ms4000001004434861, createdTime=Thu Feb 15 00:29:24 CST 2024, time=2024-02-15, status=1, ipAttribution=艾奥瓦), GetPortalCommentsPageByObjectIdResponse(id=2142526, encodeId=cc68214252668, content=提交之后一直没收到邮件正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf12055441, createdName=来来搞起, createdTime=Tue Jun 13 09:30:29 CST 2023, time=2023-06-13, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1226798, encodeId=6d8c1226e9811, content=我觉得jacc系列是最友好的了，硕士投了一篇jacc：cardiovascular interventions 顺利接收，今天接收了一篇纯基础的basic to translational science，真的很开心😃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=343, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d16b5214664, createdName=14768f19m17暂无昵称, createdTime=Thu Jun 16 14:05:52 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2122361, encodeId=e2ea21223619e, content=问问各位大佬，参考文献的引用不能使用Endnote，意思是要自己一条一条按要求添加吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba658566226, createdName=ms7000001526503726, createdTime=Tue Mar 28 21:59:09 CST 2023, time=2023-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116649, encodeId=826c111664932, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:56 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1116650, encodeId=50741116650c3, content=投稿时候是否一定要提供每个作者的ORCIDID?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:56 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078119, encodeId=dc7e10e811979, content=文章质量挺不错的难度应该跟atvb同级略低于atvb, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=273, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b2d51658575, createdName=zwjxyzcl, createdTime=Wed Dec 08 15:57:58 CST 2021, time=2021-12-08, status=1, ipAttribution=)]

2021-12-08 zwjxyzcl

文章质量挺不错的难度应该跟atvb同级略低于atvb

273 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务